Federal contract award
75N91020F00006
NIAID VRC
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NIH NCI |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | 75N91019D00024 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $121.5M |
| Current contract value | $125.8M |
| Potential contract value / ceiling | $125.8M |
| Start date | Aug 31, 2020 |
| Current end date | Aug 30, 2024 |
| Potential end date | Aug 30, 2024 |
| Latest award activity | Jun 18, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 17 of 17 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 18, 2026 | P00016 | $-361 | FY26 UDO INITIATIVE |
| Aug 16, 2024 | P00015 | $882.4K | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Jun 24, 2024 | P00014 | $6.0M | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Oct 18, 2023 | P00013 | $0 | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Aug 29, 2023 | P00012 | $27.3M | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Aug 4, 2023 | P00011 | $1.6M | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Jul 13, 2023 | P00010 | $1.0M | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Apr 28, 2023 | P00009 | $5.9M | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Mar 6, 2023 | P00008 | $7.0M | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Aug 22, 2022 | P00007 | $19.5M | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Jun 14, 2022 | P00006 | $3.1M | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| May 18, 2022 | P00005 | $0 | NIAID VRC OPERATIONAL TASK ORDER; COVID: VRC IS ENGAGED IN EVALUATING MRNA VACCINES FOR DIFFERENT VARIANTS IN ANIMAL MODELS SO THAT AN EFFECTIVE MRNA VACCINE IS RECOGNIZED. THE MOST EFFECTIVE CONSTRUCTS ARE FURTHER DEVELOPED LEADING TO PRODUCTION UND |
| Aug 26, 2021 | P00004 | $23.1M | NIAID VRC |
| Jul 28, 2021 | P00003 | $0 | NIAID VACCINE RESEARCH CENTER (VRC) |
| Jul 23, 2021 | P00002 | $3.7M | NIAID VRC |
| Jul 15, 2021 | P00001 | $500.0K | NIAID VRC |
| Aug 26, 2020 | 0 | $22.0M | NIAID VRC |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.